Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma

NCT02227914 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Study stopped due to administrative reasons

Conditions

Advanced Hepatocellular Carcinoma

Interventions

DRUG: Oprozomib
DRUG: Sorafenib

Sponsor

Amgen